Medical Research Council

mrc.ukri.org

The MRC, part of UK Research and Innovation, is a publicly funded organisation dedicated to improving human health through world-class medical research. We support research across the entire spectrum of medical sciences, in universities and hospitals, in our own units and institutes in the UK, and in our units in Africa.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

VIEWS AND ANALYSIS, PHARMA TECH

ANAQUA AND PATSNAP TEAM UP TO DELIVER AN END-TO-END PHARMA IP MANAGEMENT SOLUTION

Anaqua and PatSnap | December 08, 2022

news image

Anaqua, the leading provider of innovation and intellectual property management technology announced it is partnering with innovation intelligence platform PatSnap. The collaboration will deliver an enhanced IP management solution to provide Anaqua’s pharmaceutical industry clients with a more detailed and informed view of the market and competitive landscape for key use cases. The combined Anaqua AQX® Pharma and PatSnap Synapse solutions will help AQX Pharma clients further enhance co...

Read More

Pharma Tech

SONY AND ASTELLAS ENTER INTO COLLABORATIVE RESEARCH AGREEMENT TO DISCOVER A NOVEL ADC PLATFORM FOR THE ONCOLOGY FIELD

PRNewswire | May 17, 2023

news image

Sony Corporation and Astellas Pharma Inc. announced that they have entered into a collaborative research agreement to discover a novel Antibody-Drug Conjugate (ADC) platform in oncology based on Sony's unique polymeric material, "KIRAVIA™*2 Backbone." ADC is expected to selectively deliver anti-cancer drugs to target cells, thereby increasing efficacy and reducing side effects caused by anti-cancer drugs attacking normal cells. The technology to create linkers which con...

Read More

Business Insights

JAZZ PHARMACEUTICALS ANNOUNCES AGREEMENT TO DIVEST SUNOSI® (SOLRIAMFETOL) TO AXSOME THERAPEUTICS

Jazz Pharmaceuticals plc | March 28, 2022

news image

Jazz Pharmaceuticals plc announced that it has entered into a definitive agreement to divest Sunosi® a dual-acting dopamine and norepinephrine reuptake inhibitor shown to improve wakefulness in adults living with excessive daytime sleepiness due to narcolepsy or obstructive sleep apnea to Axsome Therapeutics. Under the terms of the agreement, Axsome will receive the rights to Sunosi in all of the existing territories available to Jazz. Jazz will receive attractive financial terms including a...

Read More

Business Insights

WUXI STA OPENS NEW LARGE-SCALE OLIGONUCLEOTIDE AND PEPTIDE MANUFACTURING FACILITY

WuXi STA | July 07, 2022

news image

WuXi STA, a subsidiary of WuXi AppTec, announced the opening of a new large-scale oligonucleotide and peptide manufacturing facility at its Changzhou campus. The new facility underscores WuXi STA's ongoing commitment to enhance its capacity and capability to meet the fast-growing customer needs for oligonucleotide and peptide therapeutics development and manufacturing worldwide, making more innovative therapies accessible to the patients. With the opening of the new 30,570 sq....

Read More
news image

VIEWS AND ANALYSIS, PHARMA TECH

ANAQUA AND PATSNAP TEAM UP TO DELIVER AN END-TO-END PHARMA IP MANAGEMENT SOLUTION

Anaqua and PatSnap | December 08, 2022

Anaqua, the leading provider of innovation and intellectual property management technology announced it is partnering with innovation intelligence platform PatSnap. The collaboration will deliver an enhanced IP management solution to provide Anaqua’s pharmaceutical industry clients with a more detailed and informed view of the market and competitive landscape for key use cases. The combined Anaqua AQX® Pharma and PatSnap Synapse solutions will help AQX Pharma clients further enhance co...

Read More
news image

Pharma Tech

SONY AND ASTELLAS ENTER INTO COLLABORATIVE RESEARCH AGREEMENT TO DISCOVER A NOVEL ADC PLATFORM FOR THE ONCOLOGY FIELD

PRNewswire | May 17, 2023

Sony Corporation and Astellas Pharma Inc. announced that they have entered into a collaborative research agreement to discover a novel Antibody-Drug Conjugate (ADC) platform in oncology based on Sony's unique polymeric material, "KIRAVIA™*2 Backbone." ADC is expected to selectively deliver anti-cancer drugs to target cells, thereby increasing efficacy and reducing side effects caused by anti-cancer drugs attacking normal cells. The technology to create linkers which con...

Read More
news image

Business Insights

JAZZ PHARMACEUTICALS ANNOUNCES AGREEMENT TO DIVEST SUNOSI® (SOLRIAMFETOL) TO AXSOME THERAPEUTICS

Jazz Pharmaceuticals plc | March 28, 2022

Jazz Pharmaceuticals plc announced that it has entered into a definitive agreement to divest Sunosi® a dual-acting dopamine and norepinephrine reuptake inhibitor shown to improve wakefulness in adults living with excessive daytime sleepiness due to narcolepsy or obstructive sleep apnea to Axsome Therapeutics. Under the terms of the agreement, Axsome will receive the rights to Sunosi in all of the existing territories available to Jazz. Jazz will receive attractive financial terms including a...

Read More
news image

Business Insights

WUXI STA OPENS NEW LARGE-SCALE OLIGONUCLEOTIDE AND PEPTIDE MANUFACTURING FACILITY

WuXi STA | July 07, 2022

WuXi STA, a subsidiary of WuXi AppTec, announced the opening of a new large-scale oligonucleotide and peptide manufacturing facility at its Changzhou campus. The new facility underscores WuXi STA's ongoing commitment to enhance its capacity and capability to meet the fast-growing customer needs for oligonucleotide and peptide therapeutics development and manufacturing worldwide, making more innovative therapies accessible to the patients. With the opening of the new 30,570 sq....

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us